Jim Simons Ultragenyx Pharmaceutical Inc. Transaction History

Renaissance Technologies LLC

$70.6 Billion
Q2 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 208,300 shares of RARE stock, worth $7.08 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

208,300

Previous 299,600 30.47%

Holding current value

$7.08 Million

Previous $10.8 Million 30.19%

% of portfolio

0.01%

Previous 0.02%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	SELL	$31.06 - $39.3 $2.84 Million - $3.59 Million	-91,300 Reduced 30.47%	208,300 $7.57 Million
Q1 2025 May 14, 2025	BUY	$36.21 - $45.78 $1.63 Million - $2.06 Million	44,900 Added 17.63%	299,600 $10.8 Million
Q4 2024 Feb 13, 2025	BUY	$42.07 - $57.72 $3.05 Million - $4.19 Million	72,600 Added 39.87%	254,700 $10.7 Million
Q3 2024 Nov 13, 2024	BUY	$40.21 - $59.36 $7.32 Million - $10.8 Million	182,100 New	182,100 $10.1 Million
Q2 2023 Aug 11, 2023	BUY	$37.35 - $52.15 $732,060 - $1.02 Million	19,600 New	19,600 $904,000
Q1 2022 May 13, 2022	SELL	$62.2 - $84.4 $2.95 Million - $4 Million	-47,400 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$73.71 - $87.86 $1.78 Million - $2.13 Million	-24,200 Reduced 33.8%	47,400 $3.99 Million
Q3 2021 Nov 12, 2021	SELL	$77.92 - $102.4 $30.5 Million - $40 Million	-390,800 Reduced 84.52%	71,600 $6.46 Million
Q2 2021 Aug 13, 2021	BUY	$92.19 - $115.71 $29.3 Million - $36.7 Million	317,600 Added 219.34%	462,400 $44.1 Million
Q1 2021 May 13, 2021	BUY	$106.9 - $167.73 $5.35 Million - $8.39 Million	50,000 Added 52.74%	144,800 $16.5 Million
Q4 2020 Feb 10, 2021	BUY	$84.4 - $177.39 $8 Million - $16.8 Million	94,800 New	94,800 $13.1 Million

Others Institutions Holding RARE

# of Institutions

361

Shares Held

88.1M

Call Options Held

3.64M

Put Options Held

2.24M

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $2.38B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account